Hydrocodone 10325 cod

Hydrocodone 10325 cod

CASH FLOWS FROM OPERATING ACTIVITIES Net Profit / (Loss) Before Tax as per Statement of Profit and Loss,as Restated 913.5 1,062.9 2,323.0 2,478.3 3,568.1 2,703.7 4,125.3 Adjustments to reconcile Profit Before Tax to Net Cash Flows: Depreciation and Amortisation expenses 180.8 230.8 382.3 569.9 752.7 566.2 698.4 (Profit) / loss on sale / write off of assets (0.6) 3.3 11.1 8.9 22.8 21.6 10.2 Interest Expenses 193.5 194.3 266.0 473.3 871.1 601.8 449.0 Gain on Redemption of Investments - - (0.1) (0.3) - - (3.8) Provision for Diminision in Value of Investments - - 54.4 - - - - Interest income (5.8) (10.5) (15.9) (23.0) (26.3) (19.3) (29.8) Excess Provision written back - - - - - - 29.7 Provision for doubtful Trade Receivables and Loans and Advances - - 16.6 16.3 17.9 15.5 22.4 Provision for Impairment of assets - - - - - - 141.9 Operating Cash Flows before Working Capital Changes 1,281.4 1,480.8 3,037.4 3,523.4 5,206.3 3,889.5 5,443.3 Working Capital Adjustments ; Changes in Inventories (121.3) (819.1) (583.7)hydrocodone 10325 cod (2,158.3) (2,102.5) (1,hydrocodone 10325 cod 893.6) (129.8) Changes in Trade Receivables (274.0) (459.0) (879.1) (1,239.3) (1,283.3) (2,069.3) (1,603.2) Changes in Loans and Advances and Other Current Assets (153.0) (409.9) (377.0) (765.2) (689.9) (735.3) (713.3) Changes in Trade Payables 380.8 571.5 719.8 537.9 1,406.6 1,699.4 801.7 Changes in Other Current Liabilities and Provisions (114.3) 166.3 122.6 376.5 142.5 (7.3) 41.4 Cash Flows generated from Operations 999.6 530.6 2,040.0 275.0 2,679.7 883.4 3,840.1 Direct Taxes paid (108.1) (222.1) (154.4) (212.7) (784.0) (463.2) (1,022.4) Net Cash Flows generated from Operating Activities 891.5 308.5 1,885.6 62.3 1,895.7 420.2 2,817.7 Exchange rate Fluctuation arising on Consolidation (10.4) (54.4) (300.6) 263.9 (45.1) 546.0 111.3 Net Cash Flows generated from Operating Activities (A) 881.1 254.1 1,585.0 326.2 1,850.6 966.2 2,929.0 B. CASH FLOWS FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (1,377.8) (1,510.2) (2,250.0) (5,752.8) (2,439.0) (2,078.5) (1,634.4) Proceeds from sale of fixed assets 12.7 46.6 78.7 46.0 36.9 39.9 9.5 Investments in Current Investments - - (172.6) 172.6 - - (48.0) Investment in other Non Current Investments - - - (142.4) - - - Gain on Redemption of Investments - - 0.1 0.3 - - 3.8 Interest received 5.8 10.5 15.9 23.0 26.3 19.3 29.8 Net Cash Flows used in Investing activities (B)hydrocodone 10325 cod (1,359.3) (1,453.1) (2,327.9) (5,653.3) (2,375.8) (2,019.3) (1,639.3) (_InMillionsl Year Year Year Year Year Period Period Ended Ended Ended Ended Ended Ended Ended 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 C. CASH FLOWS FROM FINANCING ACTIVITIES Redemption of Preference shares - - - - (400.0) (400.0) - Issue of Equity Shares 23.3 47.9 - - - - 3,000.0 Share issue Expenses - - - (24.4) (25.7) (26.0) - Proceeds/(Repayment) from long-term borrowings 949.3 462.2 1,787.4 1,966.7 212.8 459.7 (2,117.4) Proceeds/(Repayment) from short-term borrowings (130.4) 1,149.3 (974.5) 2,705.5 1,726.4 1,722.7 (967.2) Interest Paid (174.4) (193.6) (224.4) (470.8) (833.0) (467.9) (442.7) Capital (Withdrawn)/Contributed by Minorities (14.1) (15.8) (2.0) 1,305.2 (67.9) (58.0) (204.2) Dividends paid including Tax (11.0) (55.1) (60.5) (120.9) (240.5)hydrocodone 10325 cod (240.5) (240.5) Net Cash Flows from / (used in) Financing activities (C) 642.7 1,394.9 526.0 5,361.3 372.1 990.0 (972.0)drugs similar to tramadol Net Increase / (Decrease) in Cash and Cash equivalents (A+B+C) 164.4 195.9 (216.9) 34.2 (153.1) (63.1) 317.7 Cash and Cash Equivalents at the Beginning of the Year 284.7 449.9 663.1 449.1 508.2 508.2 355.1 Cash and Cash Equivalents on account of merger 0.7 17.3 2.9 24.9 - - - Cash and Cash Equivalents at the End of the Year 449.9 663.1 449.1 508.2 355.1 445.1 672.8 Components of Cash and Cash Equivalents : Cash on hand 1.6 2.0 6.1 4.2 2.2 4.4 6.1 Balance with banks - On Current Accounts 428.3 398.8 421.7 503.5 347.1 423.3 642.6 -On Deposit Accounts 20.0 262.3 21.3 0.5 5.8 17.4 24.1 449.9 663.1 449.1 508.2 355.1 445.1 672.8 Public Issue aggregating up to ' [•] million [•] Equity Shares Fresh Issue of up to [•] Equity Shares, aggregating up to ' 2,250 million Offer for Sale of 11,621,100 Equity Shares(1) Of which: QIB Portion(2) Not more than [•] Equity Shares Of which: Anchor Investor Portion Not more than [•] Equity Shares* Net QIB Portion (assuming Anchor Investor Portion is fully subscribed) Note more than [•] Equity hydrocodone itching Shares Of which: Mutual Fund Portion [•] Equity Shares Balance for all QIBs including Mutual Funds [•] Equity Shares Non-Institutional Portion(2) Not less than [•] Equity Shares Retail Portion(2) Not less than [•] Equity Shares Pre and post-Issue Equity Shares Equity Shares outstanding prior to the Issue 114,436,276 Equity Shares Equity Shares outstanding after the Issue [•] Equity Shares Use of proceeds of this Issue See the section titled "Objects of the Issue" on page 83. Our Company will not receive any proceeds from the Offer for Sale. Our Company may in consultation with the BRLMs, allocate up to 30% of the QIB Portion to Anchor Investors on a discretionary basis out of which at least one-third will be available for allocation to domestic Mutual Funds only.



Medication online phentermine tramadol
New phentermine buy cheap phentermine
Cod meds online tramadol ultram 180
Effects of hydrocodone on the brain
Hydrocodone vicodin lortab overnight